GLPG
Galapagos NV
$37.96
Earnings Summary
Revenue | $136.35Mn |
Net Profits | $-13.31Mn |
Net Profit Margins | -9.76% |
Highlights
Galapagos NV’s revenue jumped 19.72% since last year same period to $136.35Mn in the Q1 2022. On a quarterly growth basis, Galapagos NV has generated -18.35% fall in its revenue since last 3-months.
Galapagos NV’s net profit fell -242.19% since last year same period to $-13.31Mn in the Q1 2022. On a quarterly growth basis, Galapagos NV has generated -181.41% fall in its net profits since last 3-months.
Galapagos NV’s net profit margin fell -218.77% since last year same period to -9.76% in the Q1 2022. On a quarterly growth basis, Galapagos NV has generated -199.7% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Galapagos NV post its latest quarter earnings
EPS Estimate Current Quarter | -0.68 |
EPS Estimate Current Year | -0.68 |
Highlights
Galapagos NV’s earning per share (EPS) estimates for the current quarter stand at -0.68 - a -7.06% fall from last quarter’s estimates.
Galapagos NV’s earning per share (EPS) estimates for the current year stand at -0.68.
Key Ratios
Key ratios of the Galapagos NV post its Q1 2023 earnings
Earning Per Share (EPS) | 0 |
Highlights
Galapagos NV’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2023. This indicates that the Galapagos NV has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2021-03-31 | -1.1 | 0.14 | 112.73% |
2021-06-30 | -1.27 | -0.98 | 22.83% |
2021-09-30 | -1.38 | -0.99 | 28.26% |
2021-12-31 | -1.12 | 0.25 | 122.32% |
Company Information
Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.
Organisation | Galapagos NV |
Headquarters | Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800 |
Employees | 0 |
Industry | Health Technology |
CEO | Paul Stoffels |
Discover More Earning Stocks in Health Technology Sector
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*